食管鳞癌中Ets-1 mRNA和蛋白的表达

目的检测转录因子Ets-1 mRNA和蛋白在食管不同病变组织中的表达。方法采用原位杂交和免疫组织化学SP法检测62例食管鳞癌、31例癌旁不典型增生组织及62例食管正常黏膜组织中Ets-1 mRNA和蛋白的表达情况。结果 Ets-1 mRNA和蛋白表达阳性率在正常食管黏膜、癌旁不典型增生及食管鳞癌组织中均依次升高,组间比较差别均具有统计学意义(P<0.01)。Ets-1 mRNA的阳性表达率随着食管鳞癌分级的增高而增高,但差别无统计学意义(P>0.05),而与浸润深度及淋巴结转移密切相关(P<0.05);Ets-1蛋白的表达与食管鳞癌的分级、浸润深度及淋巴结转移均密切相关(P<0.05);二者的表达与患者的性别、年龄无关(P>0.05)。Ets-1 mRNA和蛋白在食管鳞癌组织中的表达呈正相关关系(r=0.343,P<0.05)。结论 Ets-1基因表达增强可能是食管鳞癌发生的早期事件,可作为判定食管鳞癌侵袭和转移能力的一项指标。     

EBUS-TBNA标本检测荧光定量TB-PCR对纵隔淋巴结核的诊断价值

目的研究荧光定量TB-PCR法检测超声支气管镜引导下经支气管透壁针吸活检(EBUS-TBNA)标本的临床应用价值。 方法对2017年01月至2018年06月在我院呼吸内镜中心接受EBUS-TBNA检测的65例患者的临床资料进行回顾性分析,比较病理检查和病理检查联合荧光定量TB-PCR检测法对临床诊断纵膈淋巴结结核的敏感性、特异性和准确性。 结果病理检查对纵膈淋巴结核的敏感性、特异性、准确性分别是75%、83.3%、78.9%,而荧光定量TB-PCR法联合病理学检查对纵膈淋巴结核诊断的敏感性、特异性、准确率分别为90.5%、100%、94.4%。 结论针对EBUS-TBNA标本,采用病理学检查联合荧光定量TB-PCR检测法能够明显提高诊断淋巴结结核的敏感性、特异性、准确性,有利于结节病和纵隔结核、非结核分枝杆菌病的鉴别,具有很高的临床应用价值。     

Effect and mechanism of ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer

Objective： To explore the effect and mechanism of ginsenoside Rg3 （Shenyi Capsule, 参一胶囊） on the postoperative life span of patients with non-small cell lung cancer （NSCLC）. Methods： The prospective, randomized, controlled method was adopted. One hundred and thirty- three patients with NSCLC were randomly assigned to 3 groups： Shenyi Capsule group （43 cases）, combined therapy group （Shenyi Capsule plus chemotherapy, 46 cases）, and chemotherapy group （44 cases）. The survival rates, immune function and the correlation between vascular endothelial growth factor （VEGF） expression and clinical effect were analyzed in the three groups. Results： （1） The 1-year survival rate in the Shenyi group, the combined group and the chemotherapy group was 76.7% （33/43）, 82.6% （38/46）, and 79.5% （35/44）, respectively; the 2-year survival rate was 67.4% （29/43）, 71.7% （33/46）, and 70.5% （31/44）, respectively; and the 3-year survival rate was 46.5% （20/43）, 54.3% （25/46）, and 47.7% （21/44）, respectively. There was no significant difference among the 3 groups （P〉0.05）. （2） NK cells were increased to different degrees and the ratio of CD4/CD8 was normal in the Shenyi Capsule group and the combined group, while the ratio of CD4/CD8 was disproportional in the chemotherapy group. （3） In the chemotherapy group, the 3-year survival rate was lower in patients with positive expression of VEGF than in patients with negative expression （37.0% vs 64.7%, χ^2=17.9, P〈0.01）, but no significant statistical difference was shown in the other two groups （53.6% vs 55.6%, P〉0.05; 44.4% vs 50.0%, P〉0.05）. Conclusion： Shenyi Capsule, especially in combination with chemotherapy, can improve the life span of patients with NSCLC after operation. The mechanism might be correlated with improving the immune function and anti-tumor angiogenesis.